Exenatide extended-release (Bydureon/BCise) carries a boxed warning regarding thyroid C-cell tumors based on rodent studies and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
Rights and permissions About this article Cite this article Liu, H., Forouhar, F., Seibt, T
Genetic contextcombined with clinical biomarkers and symptom historycan support a more nuanced treatment discussion
Step-by-step, these develop from general exhaustion , tiredness, susceptibility to infections and disorders of the mucous membranes
After incubation, samples were washed with distilled water to remove the excess of DCFDA and fixed in the slide for fluorescent imaging (fluorescence inverted microscope, Dewinter, Italy)